Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Down 36.4% in June

Redhill Biopharma Ltd. (NASDAQ:RDHL) saw a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 14,178 shares, a drop of 36.4% from the May 31st total of 22,308 shares. Currently, 0.3% of the company’s shares are short sold. Based on an average daily volume of 737,816 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Trading of Redhill Biopharma

A hedge fund recently bought a new stake in Redhill Biopharma stock. Yorkville Advisors Global LP bought a new stake in Redhill Biopharma Ltd. (NASDAQ:RDHL) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma accounts for about 0.3% of Yorkville Advisors Global LP’s investment portfolio, making the stock its 19th biggest holding. Yorkville Advisors Global LP owned 7.57% of Redhill Biopharma as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 7.20% of the company’s stock.

Redhill Biopharma Stock Performance

RDHL stock opened at $0.81 on Friday. Redhill Biopharma has a 1 year low of $0.71 and a 1 year high of $3.31. The firm has a market cap of $4.22 million, a P/E ratio of 0.00 and a beta of 4.98. The stock has a 50-day simple moving average of $0.94 and a 200-day simple moving average of $1.00.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Redhill Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 6th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Redhill Biopharma currently has a consensus rating of “Sell”.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.